Jia Ruan, M.D., Ph.D., an associate professor at Weill Cornell Medical College, reported at the recent ASH conference about sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for mantle cell lymphoma (MCL).
This is the first phase II study to explore the combination of rituximab and lenalidomide, Ruan notes. The study enrolled 38 patients with MCL, of which 84.2 percent responded to therapy. The complete remission rate with the combination was 52.6 percent. The median progression-free survival was not reached after an average of two years on therapy. These findings are remarkable, Ruan states, and demonstrated a meaningful response rate and duration.
Video originally appeared on the OncLive site.